Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minExpanding
5 minStrong Bearish
Daily trend turns down below $0.84
Key levels
Resistance$1.01
Resistance$0.92
Latest news & SEC filings
EarningsVivani Medical reports Q3 EPS of $(0.08), matching estimates
ProductVivani Medical to report early-stage data for semaglutide implant this week
DealVivani Medical gives new details on Cortigent deal progress
All VANI news →Vivani Medical develops tiny implants placed under the skin that release medicine steadily for months at a time, using its NanoPortal delivery platform. Its pipeline centers on GLP-1 implants for weight loss and type 2 diabetes, along with a version for pets created with partner Okava Pharmaceuticals. The company carries out research and testing in the United States and Australia, and it also owns Cortigent, a subsidiary working on neurostimulation devices.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$4.00
SEPT Mid Target
$4.00
SEPT High Target
$4.00
Analyst Consensus
$4.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VANI.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$3.14
2
Moat Score
NONE
1/9
Piotroski Score
-5.5
Altman Z-Score
Insider Signal
BUYING
9 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Williams Gregg | director 10% owner | Buy | 1,587,301 | $2.0M | May 15, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
0%
FCF Growth YoY
-19.4%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for VANI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:51 | $1.15 | 1,000 | $$1K | BUY |
| 20:36:50 | $1.13 | 4,854 | $$5K | BUY |
| 20:36:50 | $1.13 | 1,800 | $$2K | BUY |
| 20:36:03 | $1.13 | 2,860 | $$3K | SELL |
| 20:23:49 | $1.12 | 4,992 | $$6K | BUY |
5 dark pool trades shown · $$17K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Vivani Medical, Inc. (VANI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Vivani Medical, Inc. (VANI) is at $0.90, down 20.05% (-$0.23) at the Nov 12, 2026 close.
Latest VANI news — Nov 11, 2026: Vivani Medical reports Q3 EPS of $(0.08), matching estimates · Nov 11, 2026: Vivani Medical to report early-stage data for semaglutide implant this week
The average analyst price target for VANI is $4.00, ranging from $4 to $4, based on 1 analysts. Latest: Lake Street initiates on Jun 23, 2026.
Analyst ratings for VANI: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
VANI last reported on Aug 13, 2026: EPS -$0.07 vs -$0.08 expected — a beat of 16.0%.
VANI does not currently pay a dividend.
Resistance: $0.92, $1.01, $1.10.
Insider activity: BUYING, 9 buys and 0 sells in the last 90 days.
Nov 11, 2026: Vivani Medical reports Q3 EPS of $(0.08), matching estimates · Nov 11, 2026: Vivani Medical to report early-stage data for semaglutide implant this week · Oct 31, 2026: Vivani Medical gives new details on Cortigent deal progress